Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Hofmann, Lars Georg Emre [VerfasserIn]   i
 Utikal, Jochen [VerfasserIn]   i
 Hassel, Jessica C. [VerfasserIn]   i
Titel:Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Verf.angabe:Lars Hofmann, Andrea Forschner, Carmen Loquai, Simone M. Goldinger, Lisa Zimmer, Selma Ugurel, Maria I. Schmidgen, Ralf Gutzmer, Jochen S. Utikal, Daniela Göppner, Jessica C. Hassel, Friedegund Meier, Julia K. Tietze, Ioannis Thomas, Carsten Weishaupt, Martin Leverkus, Renate Wahl, Ursula Dietrich, Claus Garbe, Michael C. Kirchberger, Thomas Eigentler, Carola Berking, Anja Gesierich, Angela M. Krackhardt, Dirk Schadendorf, Gerold Schuler, Reinhard Dummer, Lucie M. Heinzerling
E-Jahr:2016
Jahr:13 April 2016
Umfang:20 S.
Fussnoten:Gesehen am 17.06.2019
Titel Quelle:Enthalten in: European journal of cancer
Ort Quelle:Amsterdam [u.a.] : Elsevier, 1992
Jahr Quelle:2016
Band/Heft Quelle:60(2016), Seite 190-209
ISSN Quelle:1879-0852
Abstract:Background - Anti-programmed cell death receptor-1 (PD-1) antibodies represent an effective treatment option for metastatic melanoma as well as for other cancer entities. They act via blockade of the PD-1 receptor, an inhibitor of the T-cell effector mechanisms that limit immune responses against tumours. As reported for ipilimumab, the anti-PD-1 antibodies pembrolizumab and nivolumab can induce immune-related adverse events (irAEs). These side-effects affect skin, gastrointestinal tract, liver, endocrine system and other organ systems. Since life-threatening and fatal irAEs have been reported, adequate diagnosis and management are essential. - Methods and findings - In total, 496 patients with metastatic melanoma from 15 skin cancer centers were treated with pembrolizumab or nivolumab; 242 side-effects were described in 138 patients. In 116 of the 138 patients, side-effects affected the skin, gastrointestinal tract, liver, endocrine, and renal system. Rare side-effects included diabetes mellitus, lichen planus, and pancreas insufficiency due to pancreatitis. - Conclusion - Anti-PD1 antibodies can induce a plethora of irAEs. The knowledge of them will allow prompt diagnosis and improve the management resulting in decreased morbidity.
DOI:doi:10.1016/j.ejca.2016.02.025
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/j.ejca.2016.02.025
 Volltext: http://www.sciencedirect.com/science/article/pii/S0959804916001519
 DOI: https://doi.org/10.1016/j.ejca.2016.02.025
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Adverse event
 Anti-PD-1
 Checkpoint inhibitors
 Immune-related
 Nivolumab
 Pembrolizumab
 Side-effect
 Tolerability
 Toxicity
K10plus-PPN:1667552570
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68399329   QR-Code
zum Seitenanfang